Skip to main content
Clinical Trials/KCT0002170
KCT0002170
Recruiting
未知

Moxibustion for treating cancer-related fatigue: a multicenter, assessor-blinded, randomized controlled clinical trial

Korea Institute of Oriental Medicine0 sites96 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Symptoms, signs and abnormal clinical and laboratory findings, NEC
Sponsor
Korea Institute of Oriental Medicine
Enrollment
96
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Both male and female, aged 19 or over, but under 80 years
  • 2\. Cessation of cancer\-related treatments (e.g. surgery, chemotherapy, radiotherapy, immunotherapy, except for on\-going hormone therapy, which must have been initiated at least 3 weeks prior to enrollment) at least 12 weeks before the trial
  • 3\. Continuous fatigue related to cancer treatment or cancer itself for at least 4 weeks, fulfilment of The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD\-10\-CM) diagnostic criteria for cancer\-related fatigue, and 4 and higher points in a Brief Fatigue Inventory (BFI) score
  • 4\. The Eastern Cooperative Oncology Group (ECOG) performance status \= 2
  • 5\. Willingness to participate in the trial and provide written consent

Exclusion Criteria

  • 1\. Current level of fatigue even before the diagnosis of cancer
  • 2\. Severe anemia (platelet count \< 60,000/µL, or hemoglobin \< 8 g/dL, or absolute neutrophil count \< 1,000\)
  • 3\. Receiving aggressive treatment for anemia (e.g. erythropoietin or blood transfusion)
  • 4\. Poor oral intake with a lower\-than\-normal level of serum albumin
  • 5\. Any significant sign or symptom of inflammation with C\-reactive protein \= 10 mg/L and white blood cell \> 10,000/µL
  • 6\. Abnormal findings in thyroid function test (abnormal level of Free thyroxine \[free T4] and thyroid stimulating hormone \[TSH] \< 0\.1 uIU/ml or TSH \> 5\.1 uIU/ml)
  • 7\. Abnormal findings in liver function test or renal function test, or serious liver failure or renal failure
  • (aspartate aminotransferase or alanine aminotransferase \= 2 x upper normal range, or creatinine \= 2\.0 mg/dL)
  • 8\. A score of 11 points and over in subscale of anxiety or depression in Hospital Anxiety and Depression Scale (HADS)
  • 9\. A score of 15 points and over in insomnia severity index (ISI)

Outcomes

Primary Outcomes

Not specified

Similar Trials